Corvus Pharmaceuticals, Inc. (CRVS)

Several events have impacted Corvus Pharmaceuticals' stock price in the past six months. The Q3 2025 financial results reported a net loss of $10.2 million, with R&D expenses increasing to $8.5 million, leading to a mild negative market reaction. Data presentations for soquelitinib occurred in December 2025. The anticipation of soquelitinib atopic dermatitis data in January 2026 is a significant near-term opportunity. The stock price experienced a 9.3% drop in early January 2026. Overall, the stock has fallen approximately 25% since late 2024, but increased by 30.58% between January 13, 2025, and January 9, 2026.

Information regarding specific demand seasonality for Corvus Pharmaceuticals, Inc.'s products and services is not readily available. As a clinical-stage biopharmaceutical company, its revenue from product sales is currently non-existent, and its focus is on research and development, so traditional demand seasonality does not apply.

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing immuno-oncology therapies within the Healthcare sector, specifically in the Biotechnology industry. Its major product candidates include Soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK) in Phase 1/1b and Phase 3 clinical trials; Ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor for adenosine in Phase 2 clinical trials; and Mupadolimab (CPI-006), a humanized monoclonal antibody in Phase 1b clinical trials. The company also has preclinical stage products such as CPI-182 and CPI-935.

Corvus Pharmaceuticals, Inc. is headquartered in Burlingame, California, with its base in South San Francisco, California. The company primarily develops product candidates in the United States and has strategic collaborations with Monash University, Vernalis (R&D) Limited, and Angel Pharmaceuticals Co. Ltd.

Corvus Pharmaceuticals has maintained a generally positive Wall Street coverage, receiving a consensus rating of "Moderate Buy" from analysts, with an average rating score of 2.67. Analysts have set a consensus price target of $14.25, representing a significant upside from its current price. No specific events have negatively impacted the company's brand reputation beyond general stock price fluctuations.

Corvus Pharmaceuticals, Inc. has a mixed ownership structure. Institutional investors hold between 33.19% and 46.64% of the company's stock, with major holders including Orbimed Advisors Llc and Point72 Asset Management, L.P. Retail investors hold a significant portion, ranging from 35.53% to 39% of the company. Insiders own between 22.92% and 31.30% of the stock, with Peter A. Thompson owning the most shares among individual investors.